Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells (RBCs). One trial is being conducted for patients with acute anemia, and a separate trial is being conducted for patients with chronic anemia.
Help employers find you! Check out all the jobs and post your resume.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells (RBCs). One trial is being conducted for patients with acute anemia, and a separate trial is being conducted for patients with chronic anemia.
Help employers find you! Check out all the jobs and post your resume.
